PubRank

Artur Slupianek

Author PubWeight™ 14.33‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004 1.95
2 The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002 1.55
3 Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005 1.28
4 BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008 1.22
5 BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008 1.17
6 Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002 1.17
7 Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013 1.16
8 ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle 2006 1.12
9 Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells. Blood 2007 0.81
10 Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance? Leuk Res 2003 0.81
11 Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res 2006 0.80
12 BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 2004 0.79
13 Brain tumor formation in tuberous sclerosis depends on Erk activation. Neuromolecular Med 2007 0.75
14 TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin. Anticancer Drugs 2003 0.75